FDA Prepares To Begin Search For Drug Safety Issues At Molecular Level
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination of new science and technology could allow drug developers to identify molecular risk targets, much as they look for therapeutic targets, agency tells advisory panel.
You may also be interested in...
FDA Expands Safety Signal Assessment With Mechanism-Based System
FDA will work with MolecularHealth Inc. to adapt the company’s software system, which combines molecular data with clinical data, to allow mechanism-based assessment of side effects.
FDA Looking At Genetic Factors In Vaccine Safety With New Research Group
FDA's latest target in its genomics research is vaccine safety, with a new effort to investigate how genetics contribute to vaccine reactions. The agency has hired staff and started work on strategic plans for a new, dedicated team within the Center for Biologics Evaluation and Research
FDA Looking At Genetic Factors In Vaccine Safety With New Research Group
FDA's latest target in its genomics research is vaccine safety, with a new effort to investigate how genetics contribute to vaccine reactions. The agency has hired staff and started work on strategic plans for a new, dedicated team within the Center for Biologics Evaluation and Research